突破障碍：NEK2 抑制在多发性骨髓瘤治疗中大放异彩。
Breaking barriers: NEK2 inhibition shines in multiple myeloma treatment.
机构信息
Department of Dermatology, Uniklinikum Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), 91054 Erlangen, Germany; Deutsches Zentrum für Immuntherapie (DZI), Friedrich-Alexander-University Erlangen-Nürnberg (FAU), 91054 Erlangen, Germany; Bavarian Cancer Research Center (BZKF), Erlangen, Germany.
Deutsches Zentrum für Immuntherapie (DZI), Friedrich-Alexander-University Erlangen-Nürnberg (FAU), 91054 Erlangen, Germany; Bavarian Cancer Research Center (BZKF), Erlangen, Germany; Department of Internal Medicine 5, Haematology and Oncology, Uniklinikum Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), 91054 Erlangen, Germany.
出版信息
Cell Rep Med. 2023 Oct 17;4(10):101237. doi: 10.1016/j.xcrm.2023.101237.
Abstract
In their article, Cheng et al. reveal that NEK2 loss reshapes the tumor microenvironment, reducing tumor-associated macrophages and decreasing T cell exhaustion. They show that this ultimately favors the immune system's anti-cancer response in multiple myeloma.
摘要
程等人的文章揭示，NEK2 的缺失重塑了肿瘤微环境，减少了肿瘤相关巨噬细胞，并降低了 T 细胞衰竭。他们表明，这最终有利于免疫系统对多发性骨髓瘤的抗癌反应。
相似文献
1
Breaking barriers: NEK2 inhibition shines in multiple myeloma treatment.
Cell Rep Med. 2023 Oct 17;4(10):101237. doi: 10.1016/j.xcrm.2023.101237.
2
Overexpression of NIMA related kinase 2 in multiple myeloma and its relevance with disease features and prognosis to bortezomib treatment.
J Clin Pharm Ther. 2022 Oct;47(10):1690-1697. doi: 10.1111/jcpt.13723. Epub 2022 Sep 10.
3
Genetic Aberrations and Interaction of NEK2 and TP53 Accelerate Aggressiveness of Multiple Myeloma.
Adv Sci (Weinh). 2022 Mar;9(9):e2104491. doi: 10.1002/advs.202104491. Epub 2022 Jan 27.
4
High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma.
Cell Rep Med. 2023 Oct 17;4(10):101214. doi: 10.1016/j.xcrm.2023.101214. Epub 2023 Oct 3.
5
NEK2 induces drug resistance mainly through activation of efflux drug pumps and is associated with poor prognosis in myeloma and other cancers.
Cancer Cell. 2013 Jan 14;23(1):48-62. doi: 10.1016/j.ccr.2012.12.001.
6
Nek2 is a novel regulator of B cell development and immunological response.
Biomed Res Int. 2014;2014:621082. doi: 10.1155/2014/621082. Epub 2014 Nov 17.
7
NEK2 Promotes Aerobic Glycolysis in Multiple Myeloma Through Regulating Splicing of Pyruvate Kinase.
J Hematol Oncol. 2017 Jan 13;10(1):17. doi: 10.1186/s13045-017-0392-4.
8
NEK2 plays an active role in Tumorigenesis and Tumor Microenvironment in Non-Small Cell Lung Cancer.
Int J Biol Sci. 2021 May 11;17(8):1995-2008. doi: 10.7150/ijbs.59019. eCollection 2021.
9
NEK2 induces autophagy-mediated bortezomib resistance by stabilizing Beclin-1 in multiple myeloma.
Mol Oncol. 2020 Apr;14(4):763-778. doi: 10.1002/1878-0261.12641. Epub 2020 Jan 29.
10
NIMA related kinase 2 promotes gastric cancer cell proliferation ERK/MAPK signaling.
World J Gastroenterol. 2019 Jun 21;25(23):2898-2910. doi: 10.3748/wjg.v25.i23.2898.
引用本文的文献
1
NEK2 regulates B cell function and the severity of experimental autoimmune encephalomyelitis.
J Neuroinflammation. 2025 Jun 6;22(1):152. doi: 10.1186/s12974-025-03472-w.
2
Role of NEK2 in tumorigenesis and tumor progression.
Trends Mol Med. 2025 Jan;31(1):79-93. doi: 10.1016/j.molmed.2024.07.013. Epub 2024 Aug 24.
3
The role of tumor-associated macrophages in tumor immune evasion.
J Cancer Res Clin Oncol. 2024 May 7;150(5):238. doi: 10.1007/s00432-024-05777-4.
本文引用的文献
1
High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma.
Cell Rep Med. 2023 Oct 17;4(10):101214. doi: 10.1016/j.xcrm.2023.101214. Epub 2023 Oct 3.
2
Nek2 Kinase Signaling in Malaria, Bone, Immune and Kidney Disorders to Metastatic Cancers and Drug Resistance: Progress on Nek2 Inhibitor Development.
Molecules. 2022 Jan 6;27(2):347. doi: 10.3390/molecules27020347.
3
PD-1 Blockade in Classic Hodgkin Lymphoma.
JCO Oncol Pract. 2021 Feb;17(2):72-73. doi: 10.1200/OP.20.01020. Epub 2021 Jan 13.
4
Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial.
Lancet Haematol. 2019 Sep;6(9):e459-e469. doi: 10.1016/S2352-3026(19)30110-3. Epub 2019 Jul 18.
5
How I treat myeloma with new agents.
Blood. 2017 Sep 28;130(13):1507-1513. doi: 10.1182/blood-2017-05-743203. Epub 2017 Jul 26.
6
Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study.
J Clin Oncol. 2016 Aug 10;34(23):2698-704. doi: 10.1200/JCO.2015.65.9789. Epub 2016 Jun 6.
7
Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b-2 dose-escalation study.
Lancet Haematol. 2015 Dec;2(12):e516-27. doi: 10.1016/S2352-3026(15)00197-0. Epub 2015 Nov 16.
8
Targeting the bone marrow microenvironment in multiple myeloma.
Immunol Rev. 2015 Jan;263(1):160-72. doi: 10.1111/imr.12233.
9
NEK2 induces drug resistance mainly through activation of efflux drug pumps and is associated with poor prognosis in myeloma and other cancers.
Cancer Cell. 2013 Jan 14;23(1):48-62. doi: 10.1016/j.ccr.2012.12.001.
10
The Nek2 protein kinase: a novel regulator of centrosome structure.
Oncogene. 2002 Sep 9;21(40):6184-94. doi: 10.1038/sj.onc.1205711.
Zotero 插件